| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9732075 | IDORSIA | Benzimidazole-proline derivatives |
Jun, 2033
(9 years from now) | |
| US9790208 | IDORSIA | Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10023560 | IDORSIA | Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(11 years from now) | |
Quviviq is owned by Idorsia.
Quviviq contains Daridorexant Hydrochloride.
Quviviq has a total of 3 drug patents out of which 0 drug patents have expired.
Quviviq was authorised for market use on 07 April, 2022.
Quviviq is available in tablet;oral dosage forms.
Quviviq can be used as treatment of insomnia.
Drug patent challenges can be filed against Quviviq from 2026-04-07.
The generics of Quviviq are possible to be released after 02 December, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 7, 2027 |
Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient
NCE-1 date: 2026-04-07
Market Authorisation Date: 07 April, 2022
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
QUVIVIQ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic